Ray Therapeutics' Co-Founder and CEO, Paul Bresge, joins Host Erin Harris to talk about optogenetics and how the company’s optogenetics approach differs from other gene therapies on the market ...
Single-use (SU) systems show significant promise for antibody-drug conjugate (ADC) manufacturing. However, the use of organic solvents in the ADC process raises concerns about potential leachables ...
Over the past decade, advances in drug discovery and clinical development have led to a rise in the number of approved therapies, resulting in an increasingly competitive marketplace. These evolving ...
We live in an era of extraordinary scientific advancement, and as a result, we are seeing rapid growth in the development of new drugs. When the clinical trial ecosystem works, we deliver on our ...
The rapid adoption of AI in the pharmaceutical market has led to a revolution in the research process and pharmaceutical development techniques. The AI revolution is not free of risks, however. This ...